Should You Invest in Teva Pharmaceutical (TEVA), Here’s What the Street Has to Say

Core Insights - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is recognized as one of the best-performing foreign stocks to buy, with Wall Street showing bullish sentiment following its fiscal Q4 2025 earnings release [1][3] Financial Performance - In fiscal Q4 2025, Teva reported revenue of $4.71 billion, reflecting an 11.4% year-over-year growth and exceeding Wall Street estimates by $385.8 million [3] - The earnings per share (EPS) for the quarter was $0.92, surpassing estimates by $0.32 [3] Growth Drivers - The strong performance is attributed to growth in key innovative brands such as AUSTEDO, AJOVY, and UZEDY, which collectively generated over $1 billion in revenue for the first time [4] - Analysts at Truist view the company as being in the early stages of expansion, with a notable pipeline including an FDA decision on Olanzapine LAI, which could present a $3 billion peak sales opportunity in schizophrenia treatments [4] Analyst Ratings and Price Targets - Goldman Sachs analyst Matthew Dellatorre reiterated a Buy rating on Teva and raised the price target from $36 to $45 [1] - Trust Financial also increased its price target from $36 to $38 while maintaining a Buy rating [1] Stock Performance - Teva's share price has increased by over 105% in the past year, driven by the resolution of key challenges and improved execution across its portfolio [5] - Despite trading above its historical multiple, the stock is considered attractively valued due to improved business profile, revenue expansion, margin improvements, and debt reduction [5] Company Overview - Teva develops, produces, and sells medicines across various geographical segments, including the US, Europe, and International Markets, covering specialty, generics, and over-the-counter (OTC) products [6]